Literature DB >> 11165244

Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10).

M P Crump1, E Elisseeva, J Gong, I Clark-Lewis, B D Sykes.   

Abstract

Kaposi's sarcoma-associated herpesvirus encodes a chemokine called vMIP-II that has been shown to be a broad range human chemokine receptor antagonist. Two N-terminal peptides, vMIP-II(1-10) and vMIP-II(1-11)dimer (dimerised through Cys11) were synthesised. Both peptides are shown to bind the CXC chemokine receptor 4 (CXCR4). vMIP-II(1-10) was 1400-fold less potent than the native protein whilst the vMIP-II(1-11)dimer was only 180-fold less potent. In addition, both peptides are CXCR4 antagonists. Through analysis of non-standard, long mixing time two-dimensional nuclear Overhauser enhancement spectroscopy experiments, 13C relaxation data and amide chemical shift temperature gradients for the N-terminus of vMIP-II, we show that this region populates a turn-like structure over residues 5-8, both in the presence and absence of the full protein scaffold. This major conformation is likely to be in fast exchange with other conformational states but it has not previously been detected in monomeric chemokine structures. This and other studies [Elisseeva et al. (2000) J. Biol. Chem. 275, 26799-26805] suggest that there may be a link between the structuring of the short N-terminal chemokine peptides and their ability to bind their receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11165244     DOI: 10.1016/s0014-5793(00)02393-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Respiratory syncytial virus(RSV)-induced allergy may be controlled by IL-4 and CX3C fractalkine antagonists and CpG ODN as adjuvant: hypothesis and implications for treatment.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

Review 2.  Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication.

Authors:  Emily Cousins; John Nicholas
Journal:  Recent Results Cancer Res       Date:  2014

Review 3.  Biophysical characterization of G-protein coupled receptor-peptide ligand binding.

Authors:  David N Langelaan; Pascaline Ngweniform; Jan K Rainey
Journal:  Biochem Cell Biol       Date:  2011-04       Impact factor: 3.626

4.  Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.

Authors:  Martyna Szpakowska; Amanda M Nevins; Max Meyrath; David Rhainds; Thomas D'huys; François Guité-Vinet; Nadine Dupuis; Pierre-Arnaud Gauthier; Manuel Counson; Andrew Kleist; Geneviève St-Onge; Julien Hanson; Dominique Schols; Brian F Volkman; Nikolaus Heveker; Andy Chevigné
Journal:  Br J Pharmacol       Date:  2018-03-23       Impact factor: 8.739

5.  Macrophage Migration Inhibitory Factor-CXCR4 Receptor Interactions: EVIDENCE FOR PARTIAL ALLOSTERIC AGONISM IN COMPARISON WITH CXCL12 CHEMOKINE.

Authors:  Deepa Rajasekaran; Sabine Gröning; Corinna Schmitz; Swen Zierow; Natalie Drucker; Maria Bakou; Kristian Kohl; André Mertens; Hongqi Lue; Christian Weber; Annie Xiao; Gary Luker; Aphrodite Kapurniotu; Elias Lolis; Jürgen Bernhagen
Journal:  J Biol Chem       Date:  2016-05-19       Impact factor: 5.157

Review 6.  The spreading of HIV-1 infection in the human organism is caused by fractalkine trafficking of the infected lymphocytes--a review, hypothesis and implications for treatment.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2007-04       Impact factor: 2.332

Review 7.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

Review 8.  Role of chemokines in tumor growth.

Authors:  Dayanidhi Raman; Paige J Baugher; Yee Mon Thu; Ann Richmond
Journal:  Cancer Lett       Date:  2007-07-12       Impact factor: 8.679

9.  Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.

Authors:  In Heon Lee; Matthew S Palombo; Xiaoping Zhang; Zoltan Szekely; Patrick J Sinko
Journal:  Eur J Pharm Biopharm       Date:  2018-06-09       Impact factor: 5.571

10.  Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases.

Authors:  Luigi Portella; Rosamaria Vitale; Stefania De Luca; Crescenzo D'Alterio; Caterina Ieranò; Maria Napolitano; Anna Riccio; Maria Neve Polimeno; Luca Monfregola; Antonio Barbieri; Antonio Luciano; Andrea Ciarmiello; Claudio Arra; Giuseppe Castello; Pietro Amodeo; Stefania Scala
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.